This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
ATH Technologies (E)
Simons, Robert L.; Packard, JenniferCase HBS-117017-EStrategySupplements the (A) case. Designed as an in-class handout.Starting at €5.74
-
Merck: Managing Vioxx (E)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-109084-EStarting at €5.74
-
Merck: Managing Vioxx (C)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-109082-EStarting at €5.74
-
ATH Technologies (C)
Simons, Robert L.; Packard, JenniferCase HBS-117015-EStrategySupplements the (A) case. Designed as an in-class handout.Starting at €5.74
-
Molino e Pastificio Tomasello, S.R.L.
Gallo, Miguel Ángel; Tomaselli, SalvatoreCase DG-1090StrategyEl caso presenta a una empresa italiana dedicada a la producción y comercialización de pastas alimenticias. Se trata de una empresa familiar con aproximadamente 100 años de historia, actualmente dirigida por cuatro ramas familiares procedentes de la familia fundadora. Hay miembros de la tercera generación incorporados en la empresa. Tras un impresionante crecimiento, es la tercera empresa del mercado italiano. Se plantea la necesidad de un cambio...Starting at €8.20
-
ATH Technologies (E) (Spanish version)
Simons, Robert L.; Packard, JenniferCase HBS-118S07StrategySupplements the (A) case. Designed as an in-class handout.Starting at €5.74
-
ATH Technologies (C) (Spanish version)
Simons, Robert L.; Packard, JenniferCase HBS-118S05StrategySupplements the (A) case. Designed as an in-class handout.Starting at €5.74
-
Merck: La administración de Vioxx (E)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S06Knowledge and CommunicationStarting at €5.74
-
Merck: La administración de Vioxx (C)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S04Knowledge and CommunicationStarting at €5.74
-
Managing Vioxx (A) (Spanish version)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S02Strategy(B) evidence of life-threatening side effects, (C) decision options, (D) announcement to withdraw Vioxx, (E) reaction by patients, shareholders, media, and regulators, (F) Merck fights back, and (G) wrap-up. At the end of the case series, students may conclude that doing the right thing sometimes requires very hard choices.Starting at €8.20